Hong Kong-listed firm leverages AI to transform traditional drug discovery approach
Chief scientific officer at XtalPi says AI can cut average drug discovery times to one to two years
XtalPi Holdings, an artificial intelligence (AI) drug discovery firm based in the Greater Bay Area, aims to transform the biopharmaceutical industry. The company’s approach includes leveraging AI and robotics to transform the traditional approach to drug development. Founded in 2014, the company created its own large language model (LLM), an innovation that has helped boost its chemical experiment success rate from 20-30 per cent to 90 per cent. Zhang Peiyu, the chief scientific officer at XtalPi, spoke with the Post during the China Conference: Greater Bay Area 2025 in Guangzhou. Zhang said the integration of robotics and AI will reduce drug discovery timelines to about one or two years rather than the four years it often takes now.